



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

JAN 30 2008

Remailed FEB 19 2008 to corrected address

Barry J. Swanson
Swanson & Bratschun, LLC
1745 Shea Center Drive #330
Highlands Ranch, CO 80129

In Re: Patent Term Extension
Application for
U.S. Patent No. 6,051,698

Dear Mr. Swanson:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 6,051,698 for a period of 944 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website: <http://www.fda.gov/opacom/morechoices/fdaforms/default.html> (<http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf>).

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at mary.till@uspto.gov.

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
HFD-7
5600 Fishers Lane (Rockwall II Rm 1101)
Rockville, MD 20857

RE: Macugen® (pegaptanib sodium)
FDA Docket No.: 2005E-0234

Attention: Beverly Friedman